AbbVie announced that its Phase 2b study evaluating upadacitinib in adults with non-segmental vitiligo met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index at week 24 with the 11 mg and 22 mg doses versus placebo.
